Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT02118467
PHASE4

Vasoactive Drugs in Intensive Care Unit

Sponsor: University of Chicago

View on ClinicalTrials.gov

Summary

The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.

Official title: A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

836

Start Date

2014-05-15

Completion Date

2026-12-01

Last Updated

2026-01-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

Norepinephrine

Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.

DRUG

Epinephrine

Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.

DRUG

Phenylephrine

Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.

DRUG

Vasopressin

Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.

Locations (1)

University of Chicago Medical Center

Chicago, Illinois, United States